The company will no longer refinance its existing credit agreement, stopping Bausch Health Americas from issuing $3.25 billion in secured debt securities and rescinding its offers to redeem $3.25 billion in aggregate principal of the company’s senior secured notes due in 2022 and 2024.
In a statement made March 2, the company said it “will continue to monitor market conditions and consider opportunistic refinancing transactions from time to time.”
More articles on surgery centers:
Takeda continues non-core asset sell-off for $825M
Philadelphia researchers develop 3D modeling software for previously unviewable portion of colon
FDA awards esophageal DNA test breakthrough device designation
